323 related articles for article (PubMed ID: 12548585)
61. Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study.
Xie F; Hopkins RB; Burke N; Habib M; Angelis CD; Pasetka M; Giotis A; Goeree R
Hosp Pract (1995); 2014 Apr; 42(2):38-45. PubMed ID: 24769783
[TBL] [Abstract][Full Text] [Related]
62. Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.
Coleman RE
Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S25-31. PubMed ID: 12562048
[TBL] [Abstract][Full Text] [Related]
63. Clinical research update: zoledronate.
Body JJ
Cancer; 1997 Oct; 80(8 Suppl):1699-701. PubMed ID: 9362440
[TBL] [Abstract][Full Text] [Related]
64. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
Duivenvoorden WC; Vukmirović-Popović S; Kalina M; Seidlitz E; Singh G
Br J Cancer; 2007 May; 96(10):1526-31. PubMed ID: 17437017
[TBL] [Abstract][Full Text] [Related]
65. Bisphosphonates and breast carcinoma: present and future.
Lipton A
Cancer; 2000 Jun; 88(12 Suppl):3033-7. PubMed ID: 10898348
[TBL] [Abstract][Full Text] [Related]
66. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Coleman RE
Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
[TBL] [Abstract][Full Text] [Related]
67. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors.
Lacerna L; Hohneker J
Semin Oncol; 2003 Oct; 30(5 Suppl 16):150-60. PubMed ID: 14613036
[TBL] [Abstract][Full Text] [Related]
68. Bisphosphonates in breast cancer patients with skeletal metastases.
Shapiro CL
Hematol Oncol Clin North Am; 1994 Feb; 8(1):153-63. PubMed ID: 8150777
[TBL] [Abstract][Full Text] [Related]
69. The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.
Neville-Webbe Hl; Coleman RE
Palliat Med; 2003 Sep; 17(6):539-53. PubMed ID: 14526888
[TBL] [Abstract][Full Text] [Related]
70. [Study on the safety of rapid infusion and the efficacy of incadronate against bone metastasis of breast cancer].
Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa Y; Naito Y
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1623-8. PubMed ID: 10553421
[TBL] [Abstract][Full Text] [Related]
71. Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.
Berenson JR
Semin Oncol; 2001 Apr; 28(2 Suppl 6):25-34. PubMed ID: 11346862
[TBL] [Abstract][Full Text] [Related]
72. Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors.
Rosen L; Harland SJ; Oosterlinck W
Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S19-24. PubMed ID: 12562047
[TBL] [Abstract][Full Text] [Related]
73. [IKARUS Project--incidence of bone events in breast cancer: retrospective analysis of patients in oncological centres in the Czech Republic and Slovakia].
Fínek J; Prausová J; Cmejlová V; Cwiertka K; Svébisová H; Vyzula R; Holánek M; Bodorová M; Slavícek L; Kubecová M; Loukotková L; Neumanová R; Lepeyová K; Lysý M; Smejkal J; Soumarová R; Rysková J; Kalisová K; Machanová J; Bohusová M; Alaksa V; Stresko M; Samanová T; Kůta M; Vanásek J; Vondrácková K; Vargovcíková M; Petera J; Pritzová E; Bednarík O; Hlavácová A; Jancoková I; Szeghöová O; Dammak A; Lesková J; Chroust K; Dusek L
Klin Onkol; 2009; 22(4):154-62. PubMed ID: 19731877
[TBL] [Abstract][Full Text] [Related]
74. A single pretreatment by zoledronic acid converts metastases from osteolytic to osteoblastic in the rat.
Nyangoga H; Blouin S; Libouban H; Baslé MF; Chappard D
Microsc Res Tech; 2010 Aug; 73(8):733-40. PubMed ID: 19953666
[TBL] [Abstract][Full Text] [Related]
75. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Harvey HA
Semin Oncol; 2004 Dec; 31(6 Suppl 12):23-30. PubMed ID: 15719598
[TBL] [Abstract][Full Text] [Related]
76. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
Lipton A; Theriault RL; Hortobagyi GN; Simeone J; Knight RD; Mellars K; Reitsma DJ; Heffernan M; Seaman JJ
Cancer; 2000 Mar; 88(5):1082-90. PubMed ID: 10699899
[TBL] [Abstract][Full Text] [Related]
77. Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
Aapro M; Saad F; Costa L
Oncologist; 2010; 15(11):1147-58. PubMed ID: 21051658
[TBL] [Abstract][Full Text] [Related]
78. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.
Ali SM; Esteva FJ; Hortobagyi G; Harvey H; Seaman J; Knight R; Costa L; Lipton A
J Clin Oncol; 2001 Jul; 19(14):3434-7. PubMed ID: 11454892
[TBL] [Abstract][Full Text] [Related]
79. Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies.
Cameron D
Breast; 2003 Aug; 12 Suppl 2():S22-9. PubMed ID: 14659140
[TBL] [Abstract][Full Text] [Related]
80. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma.
Reed SD; Radeva JI; Glendenning GA; Coleman RE; Schulman KA
Am J Clin Oncol; 2005 Feb; 28(1):8-16. PubMed ID: 15685028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
